BJMO - volume 17, issue 6, october 2023
K. Vande Loock PhD, E. Van der Stock MSc, A. Debucquoy PhD, K. Emmerechts MSc, N. van Damme PhD, E. Marbaix MD
The Belgian Virtual Tumourbank (BVT) network has been set up in order to facilitate the search for samples scattered among eleven Belgian tumour biobanks that collect and store residual human tumour samples locally. To achieve this, the central database (BVTr) collects patient, technical and oncological data of human residual samples stored locally in a harmonised and standardised way. In parallel, the catalogue (BVTc) enables researchers to trace the samples required for their oncology research. The implementation of automatic and manual data quality control steps guarantees a high quality of associated data from residual tumour samples and associated materials. This article presents the results of a new quality control study on breast sample data and the possibilities for researchers searching for samples. The BVT catalogue is a valuable source of information for oncology research. The ultimate goal is to promote multidisciplinary cancer research to benefit all cancer patients.
(BELG J MED ONCOL 2023;17(6):206–10)
Read moreBJMO - volume 14, issue 6, october 2020
L. van Walle MD, J. Vandeven , C. Colpaert MD, PhD, FP. Duhoux MD, PhD, P. Neven MD, PhD, L. Van Eycken MD, N. van Damme PhD
The aim of this study is to provide a reference for the Belgian breast cancer population, offering detailed information on various patient and tumour characteristics for the breast cancer population as a whole, as well as for the different molecular subtypes. Incidence data for primary invasive breast cancer in females diagnosed in 2014 were selected in the Belgian cancer registration database and underwent individual manual reviewing of the pathology protocols. Subsequently, in 95% of the study population a surrogate molecular subtype was successfully derived, using the combined expression of oestrogen receptor, progesterone receptor, human epidermal growth factor receptor-2, and tumour differentiation grade as surrogate for the proliferation marker Ki67, in conformity with the 2011 St Gallen surrogate classification. Ultimately, differences between the molecular subtypes regarding initial presentation and histopathological features were evaluated by means of a Pearson Chi-squared test for independence. Furthermore, relative survival was calculated for the different molecular subtypes. Histologically, the large majority of the Belgian breast cancer population presents with invasive breast carcinoma of no special type (NST), formerly called invasive ductal carcinoma (75.2%), 14.5% with invasive lobular carcinoma and 5.8% with mixed ductal/lobular invasive carcinoma. Less than five percent of the population harbours less frequently occurring histological subtypes. The Belgian breast cancers are predominantly of the luminal A-like subtype (54.4%), followed by the luminal B-like HER2 negative (14.7%) and the luminal B-like HER2 positive subtype (12.2%). The mean age at diagnosis is 62 years, with almost a third of the patients being 70 years or older. One out of five patients is younger than 50 years, and in the triple negative population this group counts for 31.9%, compared to 16.6% in the luminal A-like breast carcinomas. Most patients (69.4%) are diagnosed with early stage breast cancer (clinical stage 0-II); six percent of the breast cancers are clinically metastasised at the time of diagnosis. For 19% of the patients, information on clinical stage was lacking or staging was not applicable. The unadjusted five-year relative survival proportion for the Belgian cohort is 91.4%. Luminal A-like breast cancer opposed to triple negative breast cancer have the best and worst relative survival, with respectively 96.8% and 77.4% five-year relative survival proportions.
(BELG J MED ONCOL 2020;14(6):263-73)
Read moreBJMO - volume 13, issue 1, february 2019
Ir A. Hébrant PhD, Ir , A. Jouret-Mourin MD, PhD, G. Froyen PhD, J. Van der Meulen MD, M. De Man MD, R. Salgado MD, PhD, M. van den Eynde MD, PhD, N. D’Haene MD, PhD, G. Martens MD, PhD, E. van Cutsem MD, PhD, H.A. Poirel MD, PhD, S. Tejpar MD, PhD, J-L. van Laethem MD, PhD, K. Geboes MD, PhD, P. Pauwels MD, PhD, F. Dedeurwaerdere MD, B. Maes MD, PhD, J. De Grève MD, PhD, J. Vanhuysse , P. Peeters MD, L. Vanacker MD, M. Gomez-Galdon , M. Chintinne MD, PhD, A. Hendlisz MD, PhD, G. de Hertogh MD, X. Sagaert MD, M. Peeters MD, PhD, P. Vannuffel , P. Lefesvre MD, PhD, J. Vermeij , M. Simoens , T. Van den Mooter MD, N. van Damme PhD, M. Van den Bulcke PhD
The Belgian Commission of Personalized Medicine has been created to advise the federal government on all matters related to personalised medicine in oncology, including the reimbursement of molecular tests. Here, we propose the Belgian strategy for molecular testing in the digestive tumours within a scientific-based framework. For each tested biomarker, a clinical test level is attached, which is key to establish the relevance of the test and to define the reimbursement. For each digestive tumour type, the different molecular tests are represented as decision trees with its test utility, test level and a brief technical test description.
(BELG J MED ONCOL 2019;13(1):4–10)
Read moreBJMO - volume 12, issue 1, february 2018
D. Verhoeven MD, PhD, F.P. Duhoux MD, PhD, E. de Azambuja MD, PhD, H. Wildiers MD, PhD, P. Vuylsteke MD, A. Barbeaux MD, N. van Damme PhD, E. Van Eycken MD
Limited literature is available about quality management in systemic treatment of breast cancer patients. Professionals are the key players in the identification and interpretation of quality indicators. The Belgian Society of Medical Oncology takes the lead in the field of quality management of systemic treatment for cancer, especially breast cancer. A narrow collaboration with the Belgian Cancer Registry will allow benchmarking. The results will be presented and discussed between peers of the society. This should lead to better outcomes for all Belgian centres. All Belgian Society of Medical Oncology members are called for active participation
(BELG J MED ONCOL 2018;12(1):15–21)
Read more
